Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms LATTICE; LATTICE-CD
- Sponsors Bristol-Myers Squibb
- 22 Jan 2024 Status changed from active, no longer recruiting to discontinued (due to of lack of efficacy in the short term acute phase).
- 11 Dec 2023 This trial has been completed in Netharlands, according to European Clinical Trials Database record( Global end date :23 Oct 2023)
- 05 Dec 2023 This trial has been completed in Belgium and Poland, according to European Clinical Trials Database record.